Novo Nordisk A/S ADR
(NY:
NVO
)
143.07
+0.70 (+0.49%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,909,456
Open
142.28
Bid (Size)
143.07 (4)
Ask (Size)
143.37 (2)
Prev. Close
142.37
Today's Range
142.18 - 143.69
52wk Range
75.56 - 148.15
Shares Outstanding
N/A
Dividend Yield
1.24%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Today 19:44 EDT
Patients lost more more weight on Mounjaro than Ozempic.
Via
Investor's Business Daily
3 Overlooked Giants-in-the-Making for Patient Investors
Today 12:32 EDT
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches.
Via
InvestorPlace
Performance
YTD
+40.11%
+40.11%
1 Month
-0.39%
-0.39%
3 Month
+12.25%
+12.25%
6 Month
+34.46%
+34.46%
1 Year
+82.17%
+82.17%
More News
Read More
Will NVO Provide Any Buying Opportunity?
Today 6:35 EDT
Via
Talk Markets
Novartis Stock Generating Improved Relative Strength
Today 3:00 EDT
Via
Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
Via
Benzinga
Topics
ETFs
Looking for growth without the hefty price tag? Consider NYSE:NVO.
July 05, 2024
Via
Chartmill
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
July 04, 2024
Via
Benzinga
Why Novo Nordisk Stock Is Slipping Today
July 02, 2024
Via
The Motley Fool
The 7 Best Under $10 Stocks to Buy in July 2024
July 06, 2024
Via
InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
July 06, 2024
Via
Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
July 05, 2024
Via
Benzinga
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
July 05, 2024
Via
Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
July 05, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Is It Too Late to Buy Novo Nordisk Stock?
July 05, 2024
Via
The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
July 05, 2024
Via
The Motley Fool
The 3 Best Healthcare Stocks to Buy in July 2024
July 04, 2024
Via
InvestorPlace
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
July 03, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
July 03, 2024
Via
Benzinga
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
July 03, 2024
Via
Investor's Business Daily
The 7 Best Stocks to Buy in July 2024
July 03, 2024
Via
InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Via
MarketBeat
Exposures
Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
Via
Investor's Business Daily
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
July 02, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
July 02, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.